Niox Group Plc - Company Profile
Powered by 
All the sales intelligence you need on Niox Group Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Niox Group Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Niox Group Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Niox Group Plc (Niox Group) formerly Circassia Group Plc, is a company primarily engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for asthma. The company's main product, Niox Vero, is a device used to measure the concentration of fractional exhaled nitric oxide (FeNO) in asthma patients' breath, aiding in the diagnosis and management of asthma. The company's products are used by healthcare professionals globally, particularly those specializing in respiratory diseases. Niox Group also collaborates with AstraZeneca to promote the chronic obstructive pulmonary disease (COPD) product Tudorza in the US. Niox Group's distribution network includes direct sales in the US, the UK, and Germany, as well as partnerships in other countries. Niox Group is headquartered in Oxford, England, the UK.
Headquarters
United Kingdom
Address
Magdalen Centre, 1 Robert Robinson Ave, Oxford, England, OX44GA
Website
investors.niox.com
Telephone
44 1865 405560
No of Employees
85
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NIOX (LON)
Revenue (2025)
$64.2M
16.5%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
89.2%
(2025 vs 2024)
Market Cap*
$323.8M
Net Profit Margin (2025)
XYZ
62.4%
(2025 vs 2024)
* As of and is in US$
Niox Group Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Niox Vero |
| Niox | Niox |
| Feno | Feno |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Others | In March, the company announced to be acquired by Keensight, a private equity firm. |
| 2022 | Corporate Changes/Expansions | In September, the company changed its name from Circassia Group plc to NIOX Group plc. |
| 2020 | Divestiture | In January, the company divested a minority stake worth GBP2.8 million to CIP Merchant Capital. |
Competitor Comparison
| Key Parameters | Niox Group Plc | GSK plc | ALK-Abello AS | Theravance Biopharma Inc | Verona Pharma Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | Denmark | Cayman Islands | United Kingdom |
| City | Oxford | London | Hoersholm | George Town | London |
| State/Province | England | England | - | - | England |
| No. of Employees | 85 | 66,841 | 2,753 | 90 | 221 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ian Johnson | Chairman | Executive Board | 2019 | - |
| Jonathan Emms | Chief Executive Officer; Director | Executive Board | 2025 | - |
| Sarah Duncan | Chief Financial Officer | Senior Management | 2025 | - |
| Jan Lundquist | Vice President - Supply Chain and Technical Operations | Senior Management | 2019 | - |
| Warren Sweeting | Vice President - EMEA | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer